Investigative Magnetic Resonance Imaging

Korean Society of Magnetic Resonance in Medicine (대한자기공명의과학회)
권호 표지
DOI QR코드

DOI QR Code

LI-RADS version 2018 in Patients with Prior History of Hepatocellular Carcinoma: Are LR4 Observations Enough for the Diagnosis of Recurrent HCC?

  • Kim, HeeSoo (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Choi, Joon-Il (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Bo Hyun (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Youn, Seo Yeon (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Hokun (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Dong Hwan (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Rha, Sung Eun (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2021.04.30
  • Accepted : 2021.06.10
  • Published : 2021.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We evaluated the diagnostic performance of LI-RADS version 2018 using gadoxetic acid enhanced MRI for recurrent but untreated HCC in patients with prior history of HCC. Materials and Methods: We enrolled 50 consecutive patients who 1) prior history of treatment of HCC, 2) underwent liver surgery for radiological/clinical diagnosis of new HCC between 2013 to 2018, 3) had gadoxetic acid enhanced MRI within one month before surgery, and 4) did not have more than five HCCs or infiltrative tumors only. Two radiologists reviewed MRI and determined the presence of LR3, LR4 and LR5 observations except previously treated tumors based on LI-RADS version 2018 in consensus. We sub-classified LR4 into LR4m (LR4 with major features only) and LR4u (LR4 upgraded from LR3 by ancillary features). LR4u were further sub-classified into LR4ua (with arterial phase hyperenhancement) and LR4un (without arterial phase hyperenhancement). Results: PPV for LR5, LR4 and LR3 observations for recurrent HCC were 100%, 61.5% and 25.0%, respectively. 100% (3/3) of LR4m were HCC. However, PPV of LR4u was 56.5%. PPV of LR4ua and LR4un were 73.3% and 25.0%, respectively. Sensitivity of LR5 and LR5+LR4 observations as a diagnostic threshold were 32.1% and 89.3%, respectively. Sensitivity for LR5+LR4m+LR4ua observations for diagnosis of HCC were 83.7% and significantly superior to that of LR5 without significant deterioration of specificity (75.0%). Conclusion: In patients with prior history of HCC, LR4 observations by major features or with APHE may be regarded as recurrent HCCs given high sensitivity and comparable specificity/PPV to LR5 observations.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2019R1F1A1060566).

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424 https://doi.org/10.3322/caac.21492
  2. Global Burden of Disease Liver Cancer Collaboration; Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-1691 https://doi.org/10.1001/jamaoncol.2017.3055
  3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236 https://doi.org/10.1016/j.jhep.2018.03.019
  4. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC). 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20:1042-1113 https://doi.org/10.3348/kjr.2019.0140
  5. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723-750 https://doi.org/10.1002/hep.29913
  6. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-370 https://doi.org/10.1007/s12072-017-9799-9
  7. Radiology ACo. CT/MRI LI-RADS v2018 core. Available via https://www.acr.org/-/media/ACR/Files/RADS/LIRADS/LIRADS-2018-Core.pdf?la=en. Accessed December 30, 2020
  8. Chen PJ, Chen DS, Lai MY, et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989;96:527-529 https://doi.org/10.1016/0016-5085(89)91581-3
  9. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753-758 https://doi.org/10.1016/j.jamcollsurg.2003.07.003
  10. Cucchetti A, Piscaglia F, Caturelli E, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009;16:413-422 https://doi.org/10.1245/s10434-008-0232-4
  11. Huang ZY, Liang BY, Xiong M, et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann Surg Oncol 2012;19:2515-2525 https://doi.org/10.1245/s10434-012-2269-7
  12. Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg 2006;244:265-273 https://doi.org/10.1097/01.sla.0000217921.28563.55
  13. Lee EC, Kim SH, Park H, Lee SD, Lee SA, Park SJ. Survival analysis after liver resection for hepatocellular carcinoma: a consecutive cohort of 1002 patients. J Gastroenterol Hepatol 2017;32:1055-1063 https://doi.org/10.1111/jgh.13632
  14. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003;238:703-710 https://doi.org/10.1097/01.sla.0000094549.11754.e6
  15. Chung YE, Park JY, Choi JY, Kim MJ, Park MS, Seong J. Noninvasive biomarker for predicting treatment response to concurrent chemoradiotherapy in patients with hepatocellular carcinoma. Investig Mag Reson Imaging 2019;23:351-360 https://doi.org/10.13104/imri.2019.23.4.351
  16. Choi SH, Byun JH, Kim SY, et al. Liver Imaging Reporting and Data System v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LIRADS category 4 and 5 criteria. Invest Radiol 2016;51:483-490 https://doi.org/10.1097/RLI.0000000000000258
  17. Kim YC, Min JH, Kim YK, et al. Intra-individual comparison of gadolinium-enhanced MRI using pseudo-goldenangle radial acquisition with gadoxetic acid-enhanced MRI for diagnosis of HCCs using LI-RADS. Eur Radiol 2019;29:2058-2068 https://doi.org/10.1007/s00330-018-5771-x
  18. Min JH, Kim JM, Kim YK, et al. Magnetic resonance imaging with extracellular contrast detects hepatocellular carcinoma with greater accuracy than with gadoxetic acid or computed tomography. Clin Gastroenterol Hepatol 2020;18:2091-2100 e2097 https://doi.org/10.1016/j.cgh.2019.12.010
  19. Semaan S, Vietti Violi N, Lewis S, et al. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. Eur Radiol 2020;30:1020-1030 https://doi.org/10.1007/s00330-019-06458-4
  20. Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015;275:97-109 https://doi.org/10.1148/radiol.14140690
  21. Hanna RF, Miloushev VZ, Tang A, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 2016;41:71-90 https://doi.org/10.1007/s00261-015-0592-8
  22. Hope TA, Fowler KJ, Sirlin CB, et al. Hepatobiliary agents and their role in LI-RADS. Abdom Imaging 2015;40:613-625 https://doi.org/10.1007/s00261-014-0227-5
  23. Park IK, Yu JS, Cho ES, Kim JH, Chung JJ. Pseudoglandular formation in hepatocellular carcinoma determines apparent diffusion coefficient in diffusion-weighted MRI. Investig Mag Reson Imaging 2018;22:79-85 https://doi.org/10.13104/imri.2018.22.2.79